IMMU Stock Overview
A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.32 |
| 52 Week High | SEK 16.38 |
| 52 Week Low | SEK 7.10 |
| Beta | 0.82 |
| 11 Month Change | -12.78% |
| 3 Month Change | 2.06% |
| 1 Year Change | -30.91% |
| 33 Year Change | -91.62% |
| 5 Year Change | -95.70% |
| Change since IPO | -95.11% |
Recent News & Updates
Recent updates
Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate
Aug 31
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
| IMMU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.8% | -0.4% | 0.1% |
| 1Y | -30.9% | 15.1% | 11.8% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| IMMU volatility | |
|---|---|
| IMMU Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: IMMU's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IMMU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 28 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| IMMU fundamental statistics | |
|---|---|
| Market cap | SEK 418.89m |
| Earnings (TTM) | -SEK 138.05m |
| Revenue (TTM) | SEK 6.94m |
60.3x
P/S Ratio-3.0x
P/E RatioIs IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMU income statement (TTM) | |
|---|---|
| Revenue | SEK 6.94m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.94m |
| Other Expenses | SEK 144.99m |
| Earnings | -SEK 138.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,988.03% |
| Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparison